Q-omics provides the consensus-scored TRBV5-4 profile across patient tissues and cancer cell-line models. TRBV5-4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRBV5-4 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TRBV5-4 RNA expression shows 18,521 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where TRBV5-4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRBV5-4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRBV5-4 survival associations across molecular data types. TRBV5-4 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRBV5-4 RNA expression–survival associations across cancer types. High TRBV5-4 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, BRCA, LUAD and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRBV5-4 RNA expression.
This table summarizes TRBV5-4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRBV5-4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRBV5-4 shows lower tumor expression in PAAD and LUSC and higher tumor expression in KIRC, BRCA, STAD and CHOL. The KIRC box plot shows higher TRBV5-4 RNA expression in tumor versus normal tissue (log2 FC = +1.030, t-test p < 0.001).
This table shows molecular features associated with TRBV5-4 in patient tissues and cancer cell lines. In patient samples, TRBV5-4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
